Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Organoids are feasible tridimensional models that maintain the complexity of primary and metastatic human tumors. Patient tumor tissue-derived organoids mirror the biological and physiological characteristics of parental tumors and are cost-effective in vitro models to profile sensitivity and resistance to therapies of human tumors.
Breast cancer ranks first in occurrence rate and mortality among cancers in women populations worldwide. Creative Biolabs offers a large bank of breast cancer organoid models across various breast cancer subtypes to help determine promising CAR-T therapeutic responses in vivo.
Fig.1 Establishing breast cancer organoids as in vitro models. (Ebrahimi, et al., 2022)
The established organoid models of breast cancer are evaluated on histological and molecular levels to analyze whether they are consistent with the parent tumor.
| Target Antigen | Target Description | CAR-T Products |
| CEA | The expression level of Carcinoembryonic antigen (CEA) is low in blood, but elevated in several cancer tissues, such as breast, colon, and pancreas, and is an indicator of poor prognosis for breast cancer. | Anti-CEA CAR-T |
| CD70 | CD70 is a member of TNF superfamily and is highly expressed on the surface of breast cancer, renal cell carcinoma, and some lymphomas. | Anti-CD70 CAR-T |
| c-MET | Overexpression of c-MET is found in 20-30% of breast cancers and is related to poor outcomes. | Anti-c-Met CAR-T |
| CAR-T Therapy-related Products |
|
CAR Vector Products CAR Cells CAR-viral Particle Products CAR Jurkat Cell Products CAR Lentivirus Packaging Kit Kits for CARs/TCRs Development |
| Responses of Breast Cancer Organoids to CAR-T and TCR-T Therapies |
Highlights:
|
 Fig.2 ROR1 CAR-T and WT1 TCR-T showed significant cytotoxicity against breast cancer organoids. (Dekkers, et al., 2023) |
 Fig.3 The action of engineered T cells against organoids is classified into 9 groups, from dying to engagement. (Dekkers, et al., 2023) |
Organoids developed in Creative Biolabs reliably recapitulate original tumor tissue cytology and histology and express verified antigens for your CAR-T development studies. If you want more information about our service, please contact us without hesitation.
References
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
